Draft Guidance on Fluticasone Furoate; Umeclidinium Bromide; Vilanterol Trifenatate

May 2021

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

This guidance, which interprets the Agency’s regulations on bioequivalence at 21 CFR part 320, provides product-specific recommendations on, among other things, the design of bioequivalence studies to support abbreviated new drug applications (ANDAs) for the referenced drug product. FDA is publishing this guidance to further facilitate generic drug product availability and to assist the generic pharmaceutical industry with identifying the most appropriate methodology for developing drugs and generating evidence needed to support ANDA approval for generic versions of this product.

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. FDA guidance documents, including this guidance, should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA guidances means that something is suggested or recommended, but not required.

This is a new draft product-specific guidance for industry on generic fluticasone furoate; umecclidinium bromide; vilanterol trifenatate.

Active Ingredient: Fluticasone furoate; Umeclidinium bromide; Vilanterol trifenatate
Dosage Form: Route: Powder; inhalation
Strength: 0.1 mg/Inh; EQ 0.0625 mg Base/Inh; EQ 0.025 mg Base/Inh
0.2 mg/Inh; EQ 0.0625 mg Base/Inh; EQ 0.025 mg Base/Inh

Recommended Studies: In vitro and in vivo studies

FDA recommends the following in vitro and in vivo studies to establish bioequivalence (BE) of the test (T) and reference (R) dry powder inhalers (DPIs) containing fluticasone furoate, umecclidinium bromide and vilanterol trifenatate.

In Vitro BE Studies

Recommended May 2021
FDA recommends that prospective applicants conduct the following in vitro studies for both strengths of the T and R products. For each strength, use at least three batches each of the T and R products, with no fewer than 10 units from each batch. FDA recommends that three primary stability batches be also used to demonstrate in vitro BE. The three batches of T product should be manufactured from, at minimum, three different batches of drug substance(s), excipient(s), and device components. The T product should consist of the final device constituent part and final drug constituent formulation intended to be marketed.

1. Type of study: Single actuation content (SAC)
   Design: The SAC test should be performed at the beginning (B), middle (M), and end (E) lifestages\(^1\) of the product, using a flow rate of 30 L/min, 60 L/min and 90 L/min. U.S. Pharmacopoeia (USP) <601> Apparatus B or another appropriate apparatus may be used to determine the SAC using a validated assay. The number of actuations per determination should be one. The volume of air drawn through the delivery system should be 2 L.

   **Equivalence based on:** Population bioequivalence (PBE) analysis of SAC. Refer to the product-specific guidance for *Budesonide Inhalation Suspension* for additional information regarding PBE analysis procedures.

2. Type of study: Aerodynamic particle size distribution (APSD)
   Design: The APSD test should be performed at the B and E lifestages of the product using flow rates of 28.3 L/min or 30 L/min, 60 L/min and 90 L/min. The USP <601> Apparatus 3, Apparatus 5, or another appropriate method may be used to determine APSD using a validated assay. The APSD determination of each unit should be performed with a minimum number of capsules justified by the sensitivity of the validated assay. The volume of air drawn through the delivery system should be 4 L.

   Additional comments: Drug deposition on individual sites, including the mouthpiece adapter, the induction port, the pre-separator, and each stage of the cascade impactor (CI) and the filter, is requested. Mass balance accountability should be reported based on the sum of all deposition sites. For electronic submission of the individual CI data for the T and R products, provide a timetable using the format in the appendix, and send them as part of the abbreviated new drug application (ANDA) submission for BE evaluation.

   **Equivalence based on:** PBE analysis of impactor-sized mass (ISM).\(^2\) The CI profiles representing drug deposition on the individual stages of the CI along with the mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD) and fine particle mass (FPM) should be submitted as supportive evidence for equivalent APSD.

---

\(^1\) Based on the labeled number of actuations, the terms, B lifestage, M lifestage, and E lifestage represent the first actuation(s) following the priming, the actuation(s) corresponding to 50 percent of the labeled number of actuations, and the actuation(s) corresponding to the labeled number of actuations, respectively.

\(^2\) ISM is defined as a sum of the drug mass on all stages of the CI plus the terminal filter but excluding the top CI stage because of its lack of a specified upper cutoff size limit.
Pharmacokinetic BE Study

FDA recommends that prospective applicants conduct the following pharmacokinetic (PK) BE study for both strengths of the T and R products.

1. Type of study: Fasting
   Design: Single-dose, two-way crossover
   Dose: Minimum number of inhalations that is sufficient to characterize a PK profile by using a sensitive analytical method
   Subjects: Adult males and non-pregnant females, general population
   Additional comments: (1) Subjects enrolled for in vivo studies should be trained in the use of the inhalation powders in a standard fashion, prior to each treatment session, to assure a relatively consistent inspiratory flow rate and inspiratory duration. (2) The subjects should adhere to labeling as follows: “Rinse your mouth with water after you have used the inhaler and spit the water out. Do not swallow the water.” (3) A Bio-IND is required prior to conduct of the PK study if the dose exceeds the maximum labeled single dose.

   Analytes to measure: Fluticasone furoate, umeclidinium and vilanterol in plasma

   Equivalence based on: AUC and $C_{max}$ for fluticasone furoate, umeclidinium and vilanterol. The 90% confidence intervals for the geometric mean T/R ratios of AUC and $C_{max}$ should fall within the limits of 80.00-125.00%.

Comparative Clinical Endpoint BE Study

FDA recommends that prospective applicants conduct the following comparative clinical endpoint BE study for the lowest strength of the T and R products.

1. Type of study: Comparative clinical endpoint BE study
   Design: A randomized, multiple-dose, placebo-controlled, parallel group design, at minimum consisting of a 2-week run-in period followed by a 4-week treatment period of the placebo, T or R product
   Strength: 0.1 mg/Inh; EQ 0.0625 mg Base/Inh; EQ 0.025 mg Base/Inh
   Dose: 0.1 mg/Inh; EQ 0.0625 mg Base/Inh; EQ 0.025 mg Base/Inh, one inhalation once daily

   Inclusion and exclusion criteria:

   Inclusion criteria should, at minimum, include:
   a. Adult male or female subjects of non-childbearing potential, or of childbearing potential committing to consistent and correct use of an acceptable method of birth control.
b. Diagnosis of asthma as defined by the National Asthma Education and Prevention Program (NAEPP) at least 12 weeks prior to screening.

c. Pre-bronchodilator FEV₁ of ≥ 40% and ≤ 85% of predicted value during the screening visit and on the first day of treatment.

d. ≥ 12% and 0.20 L reversibility of FEV₁ within 30 minutes following 360 mcg of salbutamol/albuterol inhalation (pMDI)

e. Patients should be stable on their chronic asthma treatment regimen for at least 4 weeks prior to screening.

f. Currently non-smoking; having not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and having had ≤ 10 pack-years of historical use.

g. Ability to replace current short-acting β-agonist (SABA) with salbutamol/albuterol inhaler for use as needed for the duration of the study. Subjects should be able to withhold all inhaled SABAs for at least 6 hours prior to lung function assessments on study visits.

h. Ability to discontinue their asthma medications (inhaled corticosteroids, long-acting muscarinic antagonist and long-acting β-agonists) during the run-in period and for remainder of the study.

i. Willingness to give their written informed consent to participate in the study.

The exclusion criteria should, at minimum, include:

a. Life-threatening asthma, defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnia, respiratory arrest or hypoxic seizures, asthma related syncopal episode(s), or hospitalizations within the past year prior to the screening or during the run-in period.

b. Significant respiratory disease other than asthma (COPD, interstitial lung disease, cystic fibrosis, bronchiectasis, tuberculosis, chronic bronchitis, emphysema, etc.).

c. Evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that, in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbates during the study.

d. Viral or bacterial, fungal or parasitic, upper or lower respiratory tract infection, or sinus, or middle ear infection within 4 weeks prior to the screening, during the run-in period, or on the day of treatment.

e. Hypersensitivity to any sympathomimetic drug (e.g., albuterol, vilanterol), to any long-acting muscarinic antagonist (e.g., umeclidinium, tiotropium, ipratropium) or to any inhaled, intranasal, or systemic corticosteroid therapy, or to milk proteins, or to excipients in the DPI.

f. Patients receiving systemic, oral, parenteral or depot corticosteroids, or Anti-IgE therapy within 12 weeks prior to screening and during the study.

g. Patients receiving β₂-blockers, anti-arrhythmics, anti-depressants, monoamine oxidase inhibitors, cytochrome P450 3A4 inhibitors, and diuretics within 4 weeks prior to the screening.

Additional Recommendations:
• The study may enroll all asthma patients who meet the inclusion and exclusion criteria or may be enriched by using a subpopulation of patients predicted to respond well to the study treatment (appropriate justification should be included for the population chosen for study).

• A clear list of permitted and restricted medications should be provided, including justification for use (or restriction) of certain classes of respiratory therapies, that considers the current standard of care for asthma.

• Subjects who discontinue from the study early should be identified, and the protocol should clearly, prospectively state how missing data will be handled in the statistical analysis and provide appropriate justification for the method chosen. The protocol should also include subject retention strategies and other plans to minimize missing data. If there are missing data, adequate justification should be provided that the missing data do not lead to biased equivalence determination. Detailed information for all subjects who are discontinued from the study should be provided.

• All spirometry should be conducted in accordance with American Thoracic Society Standards.

• The study should begin with a placebo run-in period at least 2 weeks in duration to wash out any pre-study corticosteroids and/or long-acting bronchodilators and to establish FEV₁ baseline values.

• The study protocol should include pre-specified definitions of asthma exacerbation, as well as pre-specified and appropriate escape criteria with consideration to patient safety.
• The study protocol should provide a definition of compliant subjects (e.g., used at least 75% and no more than 125% of study drug doses) and specify how compliance will be verified (e.g., by the use of subject diaries).

• To ensure study sensitivity, the T and R products should both be statistically superior to placebo ($p < 0.05$) with regard to the BE study primary endpoints.

• It is the prospective applicant’s responsibility to enroll a sufficient number of subjects for the study to demonstrate BE of the T to the R product.

• The start and stop date of concomitant medication use during the study should be provided in the data set in addition to the reason for the medication use. The prospective applicant should clearly explain whether the medication was used prior to baseline visit, during the study or both.

• All adverse events (AEs) should be reported, whether or not they are considered to be related to the treatment. The report of each AE should include, at minimum, the date of onset, description of AE, severity, relation to study medication, action taken, outcome, and date of resolution.

**BE study endpoint:** (i) Area under the serial FEV$_1$-time curve calculated from time zero to 24 hours ($AUC_{0-24h}$) on the first day of the treatment, and (ii) FEV$_1$ measured in the morning prior to the dosing of inhaled medications on the last day of a four-week treatment period.

The above two primary endpoints should be baseline adjusted (change from baseline). An FEV$_1$ baseline is defined as the average of pre-dose FEV$_1$ values of at least two time points measured in the morning of the first day of a four-week treatment period. Sampling is recommended to correspond to the same time of day as used on the last day of a four-week treatment period.

On the first day of the treatment, serial FEV$_1$ should be determined at 0, 5 and 30 min, 1, 2, 3, 4, 6, 8, 10, 12, 23, and 24 hours post-dose.

**Equivalence based on:** T/R ratio for the primary endpoints. The 90% confidence intervals for the T/R ratio for the primary endpoints should fall within the limits of 80.00 - 125.00%.

---

**Additional Information**

Formulation:

FDA recommends that the T formulation be qualitatively (Q1)$^4$ and quantitatively (Q2)$^5$ the same as the R formulation.

---

$^4$ Q1 (qualitative sameness) means that the T formulation uses the same inactive ingredient(s) as the R formulation.

$^5$ Q2 (quantitative sameness) means that concentration of the inactive ingredient(s) used in the T formulation are within ±5% of those used in the R formulation.
If a prospective applicant uses a Q2-different formulation for its T product, the prospective applicant should explain the reason(s) for not using a T formulation that is Q2 the same as the R formulation. In addition, the prospective applicant should provide pharmaceutical development data, involving in vitro testing of multiple drug-to-excipient ratios that encompass combinations below and above the ratios used in the T and R products.

Device:

Prospective applicants should refer to FDA’s guidance for industry, *Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA* which, when finalized, will provide the Agency’s current thinking on the identification and assessment of any differences in the design of the user interface for a proposed generic drug-device combination product when compared to its RLD.

FDA recommends that prospective applicants consider the following characteristics of the R product when designing the T product:
- Passive (breath-actuated) device
- Device-metered multi-dose format
- Number of doses of the R product
- External operating principles and external critical design attributes of the R product
- Size and shape of the R product
- Device resistance of the R product
- Dose indicator/counter

**Unique Agency Identifier:** PSG_209482
# APPENDIX

<table>
<thead>
<tr>
<th>Variable Name</th>
<th>Variable Type</th>
<th>Content</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Name</td>
<td>Character</td>
<td>TEST or REF</td>
<td>Identifier for product</td>
</tr>
<tr>
<td>LOT Number</td>
<td>Alphanumeric/Numeric</td>
<td>Alphanumeric/Numeric</td>
<td>Identifier for product lot</td>
</tr>
<tr>
<td>UNIT Number</td>
<td>Numeric</td>
<td>Numeric values</td>
<td>Identifier for unit must be unique for each product (e.g. #1-30 for test and #31-60 for ref).</td>
</tr>
<tr>
<td>Stage 1</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S1</td>
</tr>
<tr>
<td>Stage 2</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S2</td>
</tr>
<tr>
<td>Stage 3</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S3</td>
</tr>
<tr>
<td>Stage 4</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S4</td>
</tr>
<tr>
<td>Stage 5</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S5</td>
</tr>
<tr>
<td>Stage 6</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S6</td>
</tr>
<tr>
<td>Stage 7</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S7</td>
</tr>
<tr>
<td>Stage 8 or Filter</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S8</td>
</tr>
<tr>
<td>ISM</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>ISM</td>
</tr>
<tr>
<td>MMAD</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>MMAD</td>
</tr>
<tr>
<td>GSD</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>GSD</td>
</tr>
<tr>
<td>FPM</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>FRM</td>
</tr>
</tbody>
</table>

## Example

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>LOT</th>
<th>Unit</th>
<th>S1</th>
<th>S2</th>
<th>S3</th>
<th>S4</th>
<th>S5</th>
<th>S6</th>
<th>S7</th>
<th>S8 or Filter</th>
<th>ISM</th>
<th>MMAD</th>
<th>GSD</th>
<th>FPM</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEST</td>
<td>1234</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>